The
Zimmer Biomet Holdings' (ZBH) performance reflects a mix of events and market sentiments. The company has declared
several quarterly dividends through 2024 and beyond. Despite stock underperformance in comparison to its competitors, Zimmer Biomet has managed to outperform them on certain days. The FDA granted clearance for some of their innovative products like the
Persona® SoluTion™ PPS® Femur,
OsseoFit™ Stemless Shoulder System, and the
Oxford® Cementless Partial Knee. However, ZBH has been subject to criticism for underperformance and was ranked a bottom Quant stock by UBS. Notably,
Arnold Schwarzenegger has been appointed as the Chief Movement Officer. Zimmer Biomet also announced a definitive agreement to acquire
OrthoGrid Systems, Inc. Their Q3 2024 financial results highlight strong revenue growth. However, shareholders have unfortunately had to endure a
loss of 21%-23% in the last five years. The company has continued to face unpredictability caused by a range of factors.
Zimmer Biomet Holdings ZBH News Analytics from Thu, 08 Feb 2024 08:00:00 GMT to Sat, 21 Dec 2024 13:04:48 GMT -
Rating -1
- Innovation 7
- Information 6
- Rumor -3
